收费全文 | 11569篇 |
免费 | 589篇 |
国内免费 | 61篇 |
耳鼻咽喉 | 131篇 |
儿科学 | 241篇 |
妇产科学 | 233篇 |
基础医学 | 1393篇 |
口腔科学 | 355篇 |
临床医学 | 882篇 |
内科学 | 3008篇 |
皮肤病学 | 167篇 |
神经病学 | 1291篇 |
特种医学 | 351篇 |
外科学 | 1474篇 |
综合类 | 27篇 |
一般理论 | 3篇 |
预防医学 | 527篇 |
眼科学 | 228篇 |
药学 | 796篇 |
中国医学 | 17篇 |
肿瘤学 | 1095篇 |
2023年 | 69篇 |
2022年 | 128篇 |
2021年 | 277篇 |
2020年 | 178篇 |
2019年 | 239篇 |
2018年 | 264篇 |
2017年 | 236篇 |
2016年 | 263篇 |
2015年 | 284篇 |
2014年 | 384篇 |
2013年 | 597篇 |
2012年 | 834篇 |
2011年 | 850篇 |
2010年 | 462篇 |
2009年 | 453篇 |
2008年 | 769篇 |
2007年 | 816篇 |
2006年 | 794篇 |
2005年 | 758篇 |
2004年 | 748篇 |
2003年 | 667篇 |
2002年 | 605篇 |
2001年 | 123篇 |
2000年 | 116篇 |
1999年 | 94篇 |
1998年 | 124篇 |
1997年 | 88篇 |
1996年 | 98篇 |
1995年 | 87篇 |
1994年 | 81篇 |
1993年 | 68篇 |
1992年 | 63篇 |
1991年 | 54篇 |
1990年 | 65篇 |
1989年 | 49篇 |
1988年 | 37篇 |
1987年 | 37篇 |
1986年 | 34篇 |
1985年 | 34篇 |
1984年 | 36篇 |
1983年 | 34篇 |
1982年 | 22篇 |
1981年 | 29篇 |
1980年 | 12篇 |
1979年 | 15篇 |
1978年 | 17篇 |
1977年 | 17篇 |
1974年 | 15篇 |
1973年 | 16篇 |
1970年 | 10篇 |
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献No changes in viability, apoptosis or cell area were detected in AMs treated with As3+ concentrations up to 2 μM for 24–96 h. A marked decrease in these end-points was observed for As3+ concentrations ranging from 2.5 μM to 10 μM.
Regarding the dynamics of the endo-exocytic process triggered by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell incorporation, no variations were detected for As3+ concentrations lower than 2 μM while higher concentrations markedly modified this response.
MTT specific activity, as a measure of cell metabolic activity, was not modified irrespective of the As3+ concentration assayed. However, nitroblue tetrazolium (NBT) specific activity, as a measure of superoxide anion generation, is responsive but only to low As3+ doses.
Although this study focuses on lung macrophages, the effects of As3+ described herein may also apply to the response of macrophages residing in other organs.
Arsenite modifies the metabolic and the oxidative status of AMs in vitro. When macrophages are in an As3+ rich medium, they exhibit a reduction in respiratory burst levels and lose their intrinsic capacity to respond to toxicants. 相似文献